Smart ECM
Account
RESPhiloikos S.R.L.Evento 493187 / Edizione 1

Beyond the kidney: The bone-vascular-heart triad in CKD

Congresso internazionale su CKD-MBD: fragilità ossea, calcificazioni vascolari, iperparatiroidismo secondario, terapie antiosteoporotiche (denosumab, teriparatide) e rischio cardiovascolare nella malattia renale cronica. Venezia Mestre, 30-31 ottobre 2026.

Provider
Philoikos S.R.L.Philoikos S.R.L. (5288)
Crediti ECM
11
Costo
100,00 €
Durata
11 ore
Date
30 - 31 ottobre 2026
Richiedi info iscrizione
Aggiungi al Piano

Razionale scientifico

Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) is a major complication of chronic kidney disease, characterized by the complex interaction between bone fragility, mineral metabolism abnormalities, vascular calcification, and increased cardiovascular risk. The diagnosis and management of CKD-MBD remain challenging and require a multidisciplinary and evidence-based approach. This educational program aims to provide participants with an updated overview of the pathophysiology, diagnosis, and treatment of bone and cardiovascular complications associated with CKD. Through plenary lectures, clinical cases, and interactive discussions, the course will address key topics including osteoporosis in CKD, secondary hyperparathyroidism, bone quality assessment, vascular calcification, and emerging therapeutic strategies. Particular attention will be given to innovative treatments, cardiovascular risk factors, and the role of new technologies such as artificial intelligence in CKD-MBD management. The program also explores the impact of novel metabolic therapies on kidney, vascular, and bone health. By integrating scientific updates with practical clinical insights, the course aims to improve participants' knowledge and support a more comprehensive and personalized management of patients with CKD-MBD.

Luogo

Leonardo Royal Hotel Venice Mestre
Via Ca' Marcello, 6, Venezia (VE)

Programma

Friday, October 30, 2026 – Session 1
  • 13:00Welcome introductionMaria Fusaro, Antonio Bellasi
  • 13:15Plenary Lecture: Bone fragility: a feature of the osteoporosis associated CKDMaria Fusaro
  • 14:00Clinical Vignette: an 82-year-old lady on maintenance dialysis complaining of back painAlthea Cossettini
  • 14:10Bone quality assessmentHanne Skou Jørgensen
  • 14:40SHPT treatment: vitamin DGiovanni Tripepi
  • 15:10SHPT treatment: CaSR modulationMathias Haarhaus
  • 15:40Questions and AnswersAlthea Cossettini, Ina Karstoft Ystrøm, Silverio Rotondi, Juan Miguel Díaz Tocados
  • 16:00Coffee break – Poster Coffee Session – Oral presentation of Best Paper
Friday, October 30, 2026 – Session 2
  • 16:30Osteoporosis treatment: antiresorptive agents (denosumab, romosozumab)Pieter Evenepoel
  • 17:00Osteoporosis treatment: bone anabolic agents (teriparatide vs abaloparatide)Syazrah Salam
  • 17:30Questions and AnswersAlthea Cossettini, Ina Karstoft Ystrøm, Silverio Rotondi, Juan Miguel Díaz Tocados
Saturday, October 31, 2026 – Session 3
  • 08:30Welcome introductionMaria Fusaro, Antonio Bellasi
  • 08:45Plenary Lecture: Vascular calcification: the link between traditional and non-traditional CV risk factorsAntonio Bellasi
  • 09:15Clinical vignette: a 62-year-old man with CKD complaining of shortness of breathIna Karstoft Ystrøm
  • 09:30Traditional CV risk factors: lipid controlAlberto Zambon
  • 10:00Non-traditional CV risk factors: phosphate, PTH, FGF23 & KlothoMarc Vervloet
  • 10:30Questions and answers
  • 10:45Coffee break
Saturday, October 31, 2026 – Session 4
  • 11:00SHPT treatment in non-dialysis dependent CKD patientsCarlo Alfieri
  • 11:30Vascular calcification treatment: old and new treatmentsMario Cozzolino
  • 12:00Calciphylaxis treatment: what are the optionsSmeeta Sinha
  • 12:30Artificial Intelligence: the role in CKD-MBDMartin de Borst
  • 13:00Questions and answers
  • 13:15Lunch break
Saturday, October 31, 2026 – Session 5
  • 14:00Bone and cardiovascular involvement in primary hyperoxaluria and other stone-forming conditionsPietro Manuel Ferraro
  • 14:30SGLT2-inibitors, GLP1-RA and Dual GLP-1/GIP RA at the crossroad between kidney, vascular and bone healthSerge Ferrari
  • 15:00Questions and answers on bone and vascular imagingAlthea Cossettini, Ina Karstoft Ystrøm, Silverio Rotondi, Juan Miguel Díaz Tocados

Responsabili del corso

PHILOIKOS S.R.L.

Provider

ID Provider: N° 5288

Città: Melfi (PZ)

Tipologia: Società, Agenzie Ed Enti Privati

Stato accreditamento: Standard - 1° Rinnovo

  • Antonio Bellasi

    Responsabile scientifico

    Specializzazione: Nefrologia

    Struttura: EOC (Ente Ospedaliero Cantonale), Lugano

    Ruolo: Direttore Nephrology and Dialysis Service

  • Maria Fusaro

    Responsabile scientifico

    Specializzazione: Nefrologia

    Struttura: CNR-IFC / Università di Padova

    Ruolo: Research Nephrologist, MD PhD

Relatori e docenti

  • Carlo Maria Alfieri

    Relatore

    Specializzazione: Nefrologia

    Struttura: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano

    Ruolo: Professore Associato di Nefrologia

  • Althea Cossettini

    Relatore

    Specializzazione: Nefrologia

    Struttura: ASST Fatebenefratelli Sacco

    Ruolo: Dirigente Medico SC Nefrologia

  • Mario Cozzolino

    Relatore

    Specializzazione: Nefrologia

    Struttura: Università degli Studi di Milano Statale

    Ruolo: Professore Ordinario di Nefrologia

  • Martin de Borst

    Relatore

    Specializzazione: Nefrologia

    Struttura: University Medical Centre Groningen (UMCG), Paesi Bassi

    Ruolo: Professore di Medicina; Consulente Nefrologo

  • Juan Miguel Díaz Tocados

    Relatore

    Specializzazione: Biologia

    Struttura: Institut de Recerca Biomèdica de Lleida, Spagna

    Ruolo: Postdoctoral Researcher

Domande frequenti

L'evento è accreditato per: Medico Chirurgo (Nefrologia, Cardiologia, Ortopedia E Traumatologia).

Fonte dati per questo evento: Agenas. Evento organizzato da provider terzo. Smart ECM riporta dati pubblici dell'evento a scopo informativo e non è responsabile né del corso né dei contenuti, né ha accordi commerciali o di collaborazione con il provider.

Sei un provider ECM?

Contattaci per scoprire come possiamo collaborare.

Contattaci